A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for ...

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing processReceived FDA ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen ...

The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology ...

The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are ...

STOCKHOLM, Feb. 24, 2026 /PRNewswire/ — The clinical database has been finalized for the pre-specified interim efficacy analysis in Diamyd Medical’s ongoing pivotal Phase 3 trial (DIAGNODE-3) ...

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of ...

Tevogen ("Tevogen Bio Holdings Inc.") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding ...